1. A high-purity double virus inactivated FVIII/vWF concentrate (Immunate) in the successful treatment of patients with von Willebrand disease
- Author
-
G. Pindur, C Günther, Wolfhart Kreuz, B Eifrid, H‐H Wolf, Werner Engl, A Nitz, Peter Turecek, G. Auerswald, Jürgen Siekmann, H. Scheel, JD Schrieber, Inge Scharrer, Bruno Eberspächer, and M Koksch
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,biology ,business.industry ,Hematology ,General Medicine ,medicine.disease ,Virus ,Surgical prophylaxis ,Von Willebrand factor ,Pharmacokinetics ,hemic and lymphatic diseases ,Multicenter trial ,Immunology ,biology.protein ,Von Willebrand disease ,medicine ,In patient ,Clinical efficacy ,business ,Genetics (clinical) ,circulatory and respiratory physiology - Abstract
Patients with severe forms of von Willebrand disease (vWD) most frequently require substitution of both factor VIII and von Willebrand factor (vWF). Immunate is a high-purity, double-virus inactivated FVIII/vWF concentrate derived from human plasma. The clinical efficacy of Immunate concerning the management of acute bleeding episodes and surgical prophylaxis in patients with von Willebrand disease (vWD) is being investigated and documented in a prospective, phase III, open-label, single-armed multicenter trial. Data on its pharmacokinetics are collected, and the product's safety with respect to adverse experiences is monitored.
- Published
- 2002